Fig. 7: Dual ERBB2 and PD-1 inhibition increases MHC-I-mediated antigen presentation and T cell recruitment. | Nature Communications

Fig. 7: Dual ERBB2 and PD-1 inhibition increases MHC-I-mediated antigen presentation and T cell recruitment.

From: ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer

Fig. 7

a Schematic of the experimental setup showing treatment of autochthonous SCLC tumor-bearing mice, once lesions are detected by CT. Mice received either vehicle, anti-PD-1, ERBB2i (mubritinib), or a combination of anti-PD-1 and ERBB2i (mubritinib). After treatment, tumors were harvested and processed for scRNA-seq analysis. Created in BioRender. Meder, L. (2025) https://BioRender.com/bxcwg6c. b Treatment group annotation of cell clusters visualized in UMAP from scRNA-seq samples of four treatment conditions: vehicle (green), anti-PD-1 (orange), ERBB2i (blue), and combination anti-PD-1 and ERBB2i (red). c–e UMAP plots indicating expression of PTPRC (c), CD3e (d), EPCAM (e) in treatment groups (n = 4 mice). f–i Cell type identification of immune (orange) and epithelial tumor cells in vehicle (f), ERBB2i (g), anti-PD-1 (h) and anti-PD-1 + ERBB2i treated mice (i). The ratio of each cell fraction is represented in the pie chart in inset. j Dot plot of the mean expression of antigen-presentation-associated genes and neuroendocrine markers in the epithelial cells for each therapy group. k Dot plot of the mean expression per marker in the T cells for each therapy group. Source data are provided as a Source Data file.

Back to article page